Boehringer-Ingelheim pill Hernexeos was awarded accelerated FDA approval for advanced cases of non-small cell lung cancer with HER2 mutations. But Bayer is on its heels with an oral small molecule currently under FDA review in the same indication.
The post FDA Nod Makes Boehringer Ingelheim Drug an Alternative to AstraZeneca ADC in Lung Cancer appeared first on MedCity News.
